The enteral nutrition market size is projected to reach US$ 17,330.87 million by 2031 from US$ 10,584.80 million in 2024. The market is expected to register a CAGR of 7.3% during 2025–2031. Specific formulations and plant-based nutrition products are likely to bring in new market trends during the forecast period.
Gastrointestinal diseases include Crohn’s disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and certain cancer types. These diseases often lead to malabsorption of nutrients due to inflammation, damage, or dysfunction of the intestines. According to the “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” published in January 2021, functional gastrointestinal disorders have affected more than 40% of people across the world. Additionally, Crohn’s disease is a complex, chronic disorder primarily affecting the digestive system. It is the most common disease in North America and Europe. Research conducted by Crohn’s & Colitis UK shows that ~1 in every 123 people in the UK had either Crohn’s disease or ulcerative colitis in 2022, accounting for nearly 0.5 million people living with IBD in the UK.
According to the study “Tackling the Burden of Digestive Disorders in Europe,” published in 2023, over 332 million people are estimated to be living with a digestive disorder in European countries. As per the Guts UK, a nonprofit organization, digestive diseases that affect the gut, liver, and pancreas cause 1 in 8 deaths in the country. Similarly, short bowel syndrome (SBS) occurs in ~3 per 1 million people yearly. As per the article titled “Understanding Short Bowel Syndrome: Current Status and Future Perspectives," published in 2020, the prevalence of SBS has surged by more than twofold in the last 40 years. The prevalence of SBS was ~300 cases per 10 million in the US and ~14 cases per 10 million in Europe. Patients with gastrointestinal diseases are at an elevated risk of nutritional deterioration as they are asked to fast before undergoing diagnostic tests. They may also face nutritional deterioration due to therapeutic dietary restrictions and loss of appetite caused by anorexia or altered nutritional requirements, which can be a result of the disease itself. Thus, patients suffering from chronic diseases or those undergoing treatments for the same may require enteral nutrition to meet their daily nutrient needs.
The enteral nutrition market is rapidly expanding due to the rising incidence of chronic diseases such as cancer and diabetes, neurological disorders, and gastrointestinal diseases; rising aging population; increasing prevalence of malnutrition; and advancements in enteral feeding products, such as innovative feeding tubes, pumps, and formulas. Prominent players operating in the market are focusing on innovation and collaboration for enhanced product availability. However, the high cost of enteral nutrition products may hamper the market growth.
Undernutrition, overweight or obesity, vitamin or mineral deficiency, and poor diet-related noncommunicable diseases are all categorized under malnutrition. As per World Health Organization (WHO) data, ~1.9 billion adults were overweight or obese, whereas 462 million were underweight in 2021. Additionally, 39 million children under the age of 5 were overweight, 149 million had slow growth and development owing to the chronic lack of access to nutritious food, and 45 million were wasted (too thin for height). ~45% of deaths among children aged less than 5 are associated with undernutrition. Additionally, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the WHO in Milan, Italy, conducted a joint 46th ESPEN Congress in September 2024. The Congress reported that malnutrition affects 30–50% of hospitalized patients, 40% of oncology patients, 30–70% of older adults, 24% of hospitalized cardiovascular or pulmonary disease patients, and 38–78% of patients in intensive care units in Europe.
As per the July 2022 data by the United Nations International Children's Emergency Fund (UNICEF), the prevalence of undernourishment reached 9.3% in 2020 from 8.0% in 2019; it further jumped to 9.8% in 2021. As per the “A multi-center survey on hospital malnutrition,” published in 2021, ~33% of hospital patients in the US were either malnourished or at risk of malnutrition, and nearly 11–45% of patients in hospitals and home care settings in England suffered from malnutrition. Nutritional support can be delivered through enteral means, depending on the need, which is an essential and appropriate way of treating most malnutrition cases. Thus, the massive burden of malnutrition in children and adults drives the demand for enteral nutrition formulae and products.
Companies operating in the enteral nutrition market continuously focus on strategic developments such as collaborations, expansions, agreements, partnerships, and innovative product formulations. These strategies help them increase their sales, expand their geographic area, and enhance their capacity to cater to a larger than existing customer base. Several of the noteworthy developments in the enteral nutrition market are mentioned below.
Therefore, the introduction of innovative ready-to-drink or ready-to-use nutritional supplements, the development of innovative products targeting various health issues, and strategic moves such as expansions and acquisitions allow companies in the enteral nutrition market to create new or improved products and new businesses to remain competitive in the market. Thus, such strategic growth initiatives create significant growth opportunities in the market.
Key segments that contributed to the derivation of the enteral nutrition market analysis are type, application, and end user.
The geographic scope of the enteral nutrition market report mainly focuses on five regions: North America, Asia Pacific, Europe, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the market in 2024. It is expected to continue its dominance in the global market during the forecast period. The US is the largest market for enteral nutrition products across the globe. The market growth in the US can be associated with the burgeoning demand for medical nutrition products, particularly among aging populations and patients with chronic diseases. Additionally, the rising prevalence of obesity and diabetes has contributed to an upsurge in the number of patients needing enteral nutrition, as these conditions can result in complications that impair normal feeding and digestion. According to the International Diabetes Federation (IDF) Diabetes Atlas, 10th Edition 2021, the number of people diagnosed with diabetes in the country was 32,215 in 2021, and it is expected to rise to 36,289 by 2045.
The regional trends and factors influencing the Enteral Nutrition Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Enteral Nutrition Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 10,584.80 Million |
| Market Size by 2031 | US$ 17,330.87 Million |
| Global CAGR (2025 - 2031) | 7.3% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Enteral Nutrition Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Enteral Nutrition Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The enteral nutrition market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Below are a few of the key developments witnessed in the enteral nutrition market:
The "Enteral Nutrition Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The List of Companies - Enteral Nutrition Market
The market is expected to register a CAGR of 7.3% during 2025–2031.
The enteral nutrition market value is expected to reach US$ 17,330.87 million by 2031.
The plant-based products are likely to emerge as new, significant growth trends in the market in the coming years.
Nestlé, Danone S.A., Abbott Laboratories, FrieslandCampina, Fresenius SE and Co. KGaA, B. Braun SE, Dr. Schär AG, Arla Food, Reckitt Benckiser, Perrigo Company PLC, Fonterra Co-operative Group Limited, Kate Farms, and Nutritional Medicinals, LLC are among the main players in the market.
An increasing aging population and the rising prevalence of gastrointestinal diseases are among the most significant factors fueling the market growth.
North America dominated the market in 2024.